Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas ​

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
• Existing treatments like tyrosine kinase inhibitors and immunotherapies have limitations, necessitating novel therapeutic strategies.
• ROS1, a receptor tyrosine kinase, is implicated in NSCLC pathogenesis through rearrangement or overexpression, presenting a potential therapeutic target.

Purpose of the Study:

• To evaluate the efficacy of targeting ROS1 using immune strategies in a preclinical NSCLC model.
• To investigate ROS1 overexpression in autochthonous and metastatic NSCLC.
• To assess the therapeutic potential of ROS1-targeted electrovaccination in slowing NSCLC progression.

Main Methods:

• Utilized transgenic mice with activated K-Ras (K-Ras^G12D) that spontaneously develop metastatic NSCLC.
• Confirmed ROS1 overexpression in primary tumors, metastases, and a derived cell line using qPCR and immunohistochemistry.
• Administered intramuscular electrovaccination with plasmids encoding mouse and human ROS1 to NSCLC models.

Main Results:

• ROS1 electrovaccination significantly increased survival in mice challenged with a transplantable NSCLC cell line.
• Complete tumor rejection and immune memory were observed in a subset of electrovaccinated mice.
• Electrovaccination effectively slowed the development of autochthonous NSCLC in K-Ras^G12D mice.

Conclusions:

• Immune targeting of ROS1 via electrovaccination demonstrates significant therapeutic potential against NSCLC.
• This approach offers a promising novel strategy to improve survival outcomes for NSCLC patients.
• Further research into ROS1-targeted immunotherapies could lead to new treatment paradigms for lung cancer.